When we examined the expression of the RALGEFs in the METABRIC and TCGA BC patient cohorts, we also found that most RALGEFs (RALGDS, RGL2, RGL3, RALGPS1, RALGPS2) were significantly more highly expressed in HER2+ patients relative to the TNBC patients, while RGL1 was significantly upregulated in TNBC (Supplementary Figure S10). This evidence concerns the gene RGL3 and breast cancer.